title: The efficacy of enamel matrix derivative (Emdogain) for the treatment of deep infrabony periodontal defects: a placebo-controlled randomised clinical trial.
abstract: OBJECTIVE
  To evaluate the efficacy of Emdogain versus placebo (its carrier) for the treatment of deep infrabony defects.
  
  
  METHODS
  Thirty patients with an infrabony defect of at least 4 mm deep and at least 2 mm wide were randomly allocated for treatment with either Emdogain or placebo (the Emdogain carrier). The treating clinician was completely blinded to the therapy provided and performed all evaluations blindly up to the third year of follow-up. Outcome measures were tooth loss, complications, post-operative healing, patient's satisfaction with treatment and aesthetics, changes in probing attachment levels (PAL), probing pocket depths (PPD), gingival recessions (REC) and radiographic bone levels (RAD).
  
  
  RESULTS
  One year after treatment, both therapies had significantly improved clinical outcome measures: placebo group PAL gain = 3.3 mm, PPD reduction = 3.9 mm, and RAD gain = 2.5 mm; Emdogain group PAL gain = 3.4 mm, PPD reduction = 4.2 mm, and RAD gain = 2.5 mm. Both therapies induced statistically significant gingival recession (0.6 mm in the placebo and 0.8 mm in the Emdogain group). There were no statistically significant differences between groups for any of the outcomes tested. No teeth had to be extracted up to 3 years after treatment.
  
  
  CONCLUSIONS
  There does not appear to be any clinical advantage when using Emdogain over its carrier (placebo) in the treatment of deep and wide infrabony defects.
authors.affiliation: School of Dentistry, The University of Manchester, Manchester, UK. gabri.grusovin@tiscali.it
authors.forename: Maria Gabriella
authors.initials: MG
authors.lastname: Grusovin
authors.forename: Marco
authors.initials: M
authors.lastname: Esposito
mesh_terms: D000328:Adult; D000368:Aged; D016301:Alveolar Bone Loss / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D001861:Bone Regeneration; D016009:Chi-Square Distribution; D003746:Dental Enamel Proteins / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016037:Single-Blind Method; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D003746:Dental Enamel Proteins; C109069:enamel matrix proteins